Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
U.S. FDA approves first subcutaneous immunoglobulin replacement therapy
February 8th, 2006
ZLB Behring announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Vivaglobin (Immune Globulin Subcutaneous [Human]), an immunoglobulin (Ig) replacement therapy for treating patients with primary immunodeficiency (PI). Vivaglobin is the only FDA-approved subcutaneous (SC) Ig treatment and can be safely self-administered by PI patients under a physician's care in the United States. Vivaglobin is manufactured and marketed by ZLB Behring. Vivaglobin delivers treatment subcutaneously, directly into the skin. PI is a usually genetic group of disorders that compromise the immune system, leaving people vulnerable to...
Source: Immunotherapy Weekly (2006-02-08)
|
